Eureka-AI is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Eureka AI

415 results about "Bone cell" patented technology

Bone cell' Bone cells', which are found within the bone tissue, are responsible for the make-up of the skeleton of vertebrates. They are made up of different bone cells: there is the compact tissue which is the hard outer part of the bone, the cancellous tissue which is all the spongy tissue inside of the compact tissue, and the subchondral tissue which is the smooth tissue at the end of each bone."All About Bone." All About Bone. Ohio State University, n.d. Web. 19 Mar. 2013. Bone cells all work together inside of the bones to help keep up the skeletal system. The bone cells do many things for the skeletal system such as the development of new bones, the maintenance of bones, and the regulation of minerals in the body. Types There are four main categories of bone cells which include: lining cells, which protect the boneOursler, Merry J., and Teresita Bellido Bellido. "B>one Cells." ASBMR Educational Materials. ASBMR Educational Materials, 12 Sept. 2003. Web. 19 March 2013. Osteoclasts Osteoclasts are very large multinucleate cells that are responsible for the breakdown of bones. The breakdown of bone is very important in bone health because it allows for bone remodeling.

Bone matrix compositions and methods

The present invention provides methods of improving the osteogenic and/or chondrogenic activity of a bone matrix, e.g., a dermineralized bone matrix (DBM), by exposing the bone matrix to one or more treatments or conditions. In preferred embodiments the bone matrix is derived from human bone. The treatment or condition may alter the structure of the bone matrix and/or cleave one or more specific proteins. Cleavage may generate peptides or protein fragments that have osteoinductive, osteogenic, or chondrogenic activity. Preferred treatments include collagenase and various other proteases. The invention further provides improved bone and cartilage matrix compositions that have been prepared according to the inventive methods and methods of treatment using the compositions. The invention further provides methods of preparing, testing, and using the improved bone matrix compositions. Ona assay comprises exposing relatively undifferentiated mesenchymal cells to a bone matrix composition and measuring expression of a marker characteristic of osteoblast or chondrocyte lineage(s). Increased expression of the marker relative to the level of the marker in cells that have been exposed to a control matrix (e.g., an inactivated or untreated matrix) indicates that the treatment or condition increased the osteogenic and/or chondrogenic activity of the bone matrix. Suitable cells include C2C12 cells. A suitable marker is alkaline phosphatase. The inventive methods increase the osteogenic and/or chondrogenic activity of human DBM when tested using this assay system.

System and Method of Up-Regulating Bone Morphogenetic Proteins (Bmp) Gene Expression in Bone Cells Via the Application of Fields Generated by Specific and Selective Electric and Electromagnetic Signals

InactiveUS20070299472A1High expressionBiocideElectrotherapyHuman DNA sequencingBone Morphogenetic Protein Gene
Methods and devices are described for the regulation of bone morphogenetic protein gene expression in bone cells via the application of fields generated by specific and selective electric and electromagnetic signals in the treatment of diseased or injured bone. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased bone tissue that include generating specific and selective electric and electromagnetic signals that generate fields optimized for increase of bone morphogenetic protein gene expression and exposing bone to the fields generated by specific and selective signals so as to regulate bone morphogenetic protein gene expression in such bone tissue. The resulting methods and devices are useful for the targeted treatment of bone fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis, as an adjunct to other therapies in the treatment of one or all of the above, and in the treatment of osteoporosis.

Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same

InactiveUS20070243172A1Negative immunological responseBiocideArtificial cell constructsGerm layerDisease
The present invention relates to placenta tissue-derived multipotent stem cells and cell therapeutic agents containing the same. More specifically, to a method for producing placenta stem cells having the following characteristics, the method comprising culturing amnion, chorion, decidua or placenta tissue in a medium containing collagenase and bFGF and collecting the cultured cells: (a) showing a positive immunological response to CD29, CD44, CD73, CD90 and CD105, and showing a negative immunological response to CD31, CD34, CD45 and HLA-DR; (b) showing a positive immunological response to Oct4 and SSEA4; (c) growing attached to plastic, showing a round-shaped or spindle-shaped morphology, and forming spheres in an SFM medium so as to be able to be maintained in an undifferentiated state for a long period of time; and (d) having the ability to differentiate into mesoderm-, endoderm- and ectoderm-derived cells. Also the present invention relates to placenta stem cells obtained using the production method. The inventive multipotent stem cells have the ability to differentiate into muscle cells, vascular endothelial cells, osteogenic cells, nerve cells, satellite cells, fat cells, cartilage-forming cells, osteogenic cells, or insuline-secreting pancreatic β-cells, and thus are effective for the treatment of muscular diseases, osteoporosis, osteoarthritis, nervous diseases, diabetes and the like, and are useful for the formation of breast tissue.

Human amnion mesenchymal stem cell serum-free culture medium and culture method thereof

ActiveCN101914490ANo other animal originPassivityEmbryonic cellsGerm cellsCartilage cellsOsteoblast
The invention relates to a human amnion mesenchymal stem cell serum-free culture medium and a culture method thereof. The culture medium is formed by adding human serum albumin, human transferrin, human insulin and sodium selenite into a DMEM/F12 basic culture medium. The culture method for the culture medium comprises the following steps of: digesting human amnion by using trypsin, then digesting the human amnion by using collagenase IV and deoxyribonuclease I, and filtering the mixture to obtain single cell suspension; and adding the human serum albumin, the transferrin, the insulin and the sodium selenite into the DMEM/F12 basic culture medium in a ratio of VDMEM to VF12 of 1:1, and putting human amnion mesenchymal stem cells in a 37 DEG C CO2 incubator with saturated humidity and volume fraction of 5 percent under the serum-free condition, wherein culture in vitro and amplification are realized by solution change and transfer of culture, potentiality of multi-direction differentiation is maintained, and the amplified cells can be induced in vitro to form cartilage cells, osteoblasts and adipocytes. The culture medium and the culture method have the characteristics of no other animal sources, wide source and no limitation of ethics.

Bone tissue repair ink, composition and bracket, and preparation methods thereof as well as kit

The invention relates to the field of bone tissue engineering, in particular to bone tissue repair ink, a bone tissue repair composition and a bone tissue repair bracket, and preparation methods thereof as well as a kit. The bone tissue repair ink and a bioactive carrier wrapping cells are used as raw materials, and the bone tissue repair bracket is printed according to a preset three-dimensionalstructure by adopting a biological printer. Meanwhile, living cell printing is realized by adopting the bone tissue repair ink and the bioactive carrier as the raw materials. The cells are uniformly distributed on a bracket model formed by the bone tissue repair ink and difficultly slide down to the bottom of the bracket, so that the problem that the expression of some characteristic proteins of the cells is easily lost in the prior art is effectively solved. The growth of the cells on the bracket is facilitated. A human body bone cell growth environment is better simulated, the cell proliferation, the directional differentiation and the specific protein expression are promoted, the extension and the migration of the cells in the bone tissue bracket and the cell junction establishment arefacilitated, and an organic construction body is formed.
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products